These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 28583396)

  • 1. A novel endpoint for exacerbations in asthma to accelerate clinical development: a post-hoc analysis of randomised controlled trials.
    Fuhlbrigge AL; Bengtsson T; Peterson S; Jauhiainen A; Eriksson G; Da Silva CA; Johnson A; Sethi T; Locantore N; Tal-Singer R; Fagerås M
    Lancet Respir Med; 2017 Jul; 5(7):577-590. PubMed ID: 28583396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a novel risk score for asthma exacerbations: The risk score for exacerbations.
    Bateman ED; Buhl R; O'Byrne PM; Humbert M; Reddel HK; Sears MR; Jenkins C; Harrison TW; Quirce S; Peterson S; Eriksson G
    J Allergy Clin Immunol; 2015 Jun; 135(6):1457-64.e4. PubMed ID: 25258144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COPDCompEx: A novel composite endpoint for COPD exacerbations to enable faster clinical development.
    Vogelmeier CF; Fuhlbrigge A; Jauhiainen A; Scheepers LEJM; Bengtsson T; Peterson S; Karlsson N; Sethi T; Locantore N; Tal-Singer R; Rennard S; Fagerås M; Da Silva CA
    Respir Med; 2020 Nov; 173():106175. PubMed ID: 33032168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial.
    Papi A; Corradi M; Pigeon-Francisco C; Baronio R; Siergiejko Z; Petruzzelli S; Fabbri LM; Rabe KF
    Lancet Respir Med; 2013 Mar; 1(1):23-31. PubMed ID: 24321801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ferguson GT; FitzGerald JM; Bleecker ER; Laviolette M; Bernstein D; LaForce C; Mansfield L; Barker P; Wu Y; Jison M; Goldman M;
    Lancet Respir Med; 2017 Jul; 5(7):568-576. PubMed ID: 28545978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
    Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
    Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EXCEL: A randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma.
    Dahl R; Chuchalin A; Gor D; Yoxall S; Sharma R
    Respir Med; 2006 Jul; 100(7):1152-62. PubMed ID: 16675212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial.
    Patel M; Pilcher J; Pritchard A; Perrin K; Travers J; Shaw D; Holt S; Harwood M; Black P; Weatherall M; Beasley R;
    Lancet Respir Med; 2013 Mar; 1(1):32-42. PubMed ID: 24321802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of CompEx in eosinophilic patients with severe, uncontrolled asthma on benralizumab.
    Bolton C; Harrison T; Lugogo N; Fuhlbrigge A; Hirsch I; Bengtsson T; Peterson S; Sidaway M; Garcia Gil E; Fagerås M; Da Silva CA
    ERJ Open Res; 2024 Mar; 10(2):. PubMed ID: 38500798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
    Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
    Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two first-line therapies in the treatment of mild asthma: use of peak flow variability as a predictor of effectiveness.
    Nathan RA; Minkwitz MC; Bonuccelli CM
    Ann Allergy Asthma Immunol; 1999 May; 82(5):497-503. PubMed ID: 10353583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
    FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
    Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
    Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
    Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials.
    Hanania NA; Korenblat P; Chapman KR; Bateman ED; Kopecky P; Paggiaro P; Yokoyama A; Olsson J; Gray S; Holweg CT; Eisner M; Asare C; Fischer SK; Peng K; Putnam WS; Matthews JG
    Lancet Respir Med; 2016 Oct; 4(10):781-796. PubMed ID: 27616196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of season and geography on CompEx Asthma: a composite end-point for exacerbations.
    Jauhiainen A; Scheepers LEJM; Fuhlbrigge AL; Harrison T; Zangrilli J; Garcia Gil E; Gustafson P; Fagerås M; Da Silva CA
    ERJ Open Res; 2020 Oct; 6(4):. PubMed ID: 33123561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Forced expiratory volume in 1 second percentage improves the classification of severity among children with asthma.
    Fuhlbrigge AL; Weiss ST; Kuntz KM; Paltiel AD;
    Pediatrics; 2006 Aug; 118(2):e347-55. PubMed ID: 16864642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.
    Franciosi LG; Diamant Z; Banner KH; Zuiker R; Morelli N; Kamerling IM; de Kam ML; Burggraaf J; Cohen AF; Cazzola M; Calzetta L; Singh D; Spina D; Walker MJ; Page CP
    Lancet Respir Med; 2013 Nov; 1(9):714-27. PubMed ID: 24429275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lung function and sputum characteristics of patients with severe asthma during an induced exacerbation by double-blind steroid withdrawal.
    in't Veen JC; Smits HH; Hiemstra PS; Zwinderman AE; Sterk PJ; Bel EH
    Am J Respir Crit Care Med; 1999 Jul; 160(1):93-9. PubMed ID: 10390385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations.
    Kuna P; Peters MJ; Manjra AI; Jorup C; Naya IP; Martínez-Jimenez NE; Buhl R
    Int J Clin Pract; 2007 May; 61(5):725-36. PubMed ID: 17362472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Budesonide/formoterol maintenance and reliever therapy. A new treatment approach for adult patients with asthma].
    Korn S; Vogelmeier C; Buhl R
    Med Klin (Munich); 2008 May; 103(5):299-310. PubMed ID: 18484216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.